Not surprisingly Bioshares has put Opthea in it’s Xmas stocking as one of its 6 stock picks for 2019. Citing the company’s exceptional progress with trials this year it sees the company as being a standout investment at current prices. In addition it sees OPT-302 as having a competive advantage due to it being one of the very few drugs to target both wet AMD and DME. One further comment was the potential for a high value transaction to take place in 2020 pending positive and convincing results from both trials.
Merry Xmas everyone.
Not surprisingly Bioshares has put Opthea in it’s Xmas stocking...
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
49.8¢ |
Change
0.003(0.51%) |
Mkt cap ! $609.3M | |||
| Open | High | Low | Value | Volume |
| 49.5¢ | 49.8¢ | 49.3¢ | $10.86K | 21.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7500 | 49.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 50.0¢ | 9323 | 7 |
View Market Depth
| Last trade - 10.14am 20/08/2024 (20 minute delay) ? |
| OPT (ASX) Chart |